stay updated

Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease

Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential...

Khondrion appoints Rob van Maanen as Chief Medical Officer

NIJMEGEN, the Netherlands – Wednesday February 5th, 2020: Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies...

Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases

Study will examine impact on cognitive function from one of the most advanced disease-modifying drug treatments for mitochondrial disease in...

Khondrion becomes partner in DuSRA-VOILA collaboration

Khondrion becomes partner in DuSRA-VOILA collaboration

CEO Jan Smeitink on Khondrion’s development program and plans for 2020

On Friday 10th January 2020, CEO Jan Smeitink participated in the Annual MitoAction Town Hall Meeting alongside other companies and organisations,...

Khondrion strengthens executive team with COO Arnout Ploos van Amstel

Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces...

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

A coffee with the Scientific Advisory Board: Prof. Dr. Michelangelo Mancuso

How did you cross paths with Khondrion? I heard about Khondrion from International Mito-Patients, the global network of patient organisations, and...

Patient Perspective: A conversation with Sam’s mother

When did Sam first start experiencing symptoms and how long did it take for him to be diagnosed? Sam was first diagnosed with mitochondrial disease...

A coffee with the Scientific Advisory Board: Prof. Dr. Marni Falk

How did you cross paths with Khondrion? I have crossed paths with Jan Smeitink, Khondrion’s CEO and Founder, multiple times at various international...

Patient Perspective: A conversation with Paulien

When did you first start experiencing mitochondrial disease symptoms and how long did it take to get your diagnosis? I had a very happy and...